<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03088930</url>
  </required_header>
  <id_info>
    <org_study_id>16-2025.cc</org_study_id>
    <nct_id>NCT03088930</nct_id>
  </id_info>
  <brief_title>Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer</brief_title>
  <official_title>A Phase II Trial to Evaluate Crizotinib in the Neoadjuvant Setting in Patients With Surgically Resectable, ALK, ROS1, or MET-oncogene Positive Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy of crizotinib as induction therapy in participants with&#xD;
      surgically resectable ALK rearrangement, ROS1 rearrangement, or MET exon 14 mutation positive&#xD;
      NSCLC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants with stage IA-IIIA, surgically resectable lung adenocarcinoma with an activating&#xD;
      alteration in ALK, ROS1 or MET will receive neoadjuvant treatment with crizotinib. This&#xD;
      neoadjuvant treatment will last 6 weeks and on the last day of dosing of crizotinib,&#xD;
      participants will undergo surgical resection, followed by 5 years of follow-up via chart&#xD;
      review.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 13, 2017</start_date>
  <completion_date type="Actual">January 13, 2021</completion_date>
  <primary_completion_date type="Actual">January 13, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of participants with an objective tumor response rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>Participants' tumor response to treatment will be compared from initial/pretreatment scan to 6 week scan using RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of participants with pathologic response rate</measure>
    <time_frame>5 years follow-up</time_frame>
    <description>Pathologic response rate is defined as &lt; 50% of viable tumor present histologically in the resected tumor specimen.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of participants with metabolic response rate</measure>
    <time_frame>6 weeks post treatment</time_frame>
    <description>FDG-PET scan will measure metabolic pre-and post-induction therapy response as per PERCIST criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of participants with disease-free survival (DFS)</measure>
    <time_frame>5 years follow-up</time_frame>
    <description>DFS is defined as the time from treatment to the first of either disease recurrence or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of participants with overall survival (OS)</measure>
    <time_frame>5 years follow-up</time_frame>
    <description>OS is defined as the time from study enrollment to death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Lung Cancer, Nonsmall Cell</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant treatment with Crizotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients enrolled in this study will be treated with 6 weeks of induction therapy with crizotinib. On the last day of dosing, patients will then undergo surgical resection. 5 years of follow-up will be done via chart review.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crizotinib</intervention_name>
    <description>Crizotinib is an oral receptor tyrosine kinase inhibitor of ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), and ROS1 (c-ros). Crizotinib will be given as a neoadjuvant therapy before surgical resection. The recommended dose of crizotinib is 250mg orally. Participants on this trial will receive this dose, unless dose modification is necessary.</description>
    <arm_group_label>Neoadjuvant treatment with Crizotinib</arm_group_label>
    <other_name>Xalkori</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Stage IA-IIIA NSCLC by 8th edition AJCC staging (that is deemed to be surgically&#xD;
             resectable by a board certified thoracic surgeon.&#xD;
&#xD;
          2. Staging by PET-CT scan and MRI brain showing no evidence of metastatic disease&#xD;
             (mediastinoscopy is not required unless imaging is indeterminate and is then&#xD;
             considered standard of care)&#xD;
&#xD;
          3. Documented evidence of an ALK rearrangement (by FISH, IHC, or NGS), ROS1 rearrangement&#xD;
             (by FISH or NGS), or MET oncogene as defined by MET exon 14 skipping (NGS), MET Y1003X&#xD;
             mutation or MET gene fusion (NGS) in NSCLC tumor specimen by a CLIA-approved&#xD;
             laboratory.&#xD;
&#xD;
          4. Measurable disease defined by RECIST 1.1 criteria.&#xD;
&#xD;
          5. Life expectancy of at least 24 months.&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.&#xD;
&#xD;
          7. Age ≥ 18 years&#xD;
&#xD;
          8. Have normal QT interval on ECG evaluation QT corrected Fridericia (QTcF) of ≤ 450 ms&#xD;
             in males or ≤ 470 ms in females&#xD;
&#xD;
          9. Adequate organ function:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥1500/µL&#xD;
&#xD;
               -  Platelets ≥75,000/µL&#xD;
&#xD;
               -  Hemoglobin ≥ 10g/dL&#xD;
&#xD;
               -  AST /ALT ≤ 2.5 x upper limit of normal (ULN)&#xD;
&#xD;
               -  Total serum bilirubin ≤ 1.5 x ULN&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 x UNL&#xD;
&#xD;
               -  Serum amylase/lipase ≤ 1.5 x UNL&#xD;
&#xD;
         10. Negative serum pregnancy test within 7 days of D1 of treatment in women of child&#xD;
             bearing potential.&#xD;
&#xD;
         11. If fertile, willing to use highly effective form of contraception (defined as a&#xD;
             combination of at least two of the following methods: condom or other barrier methods,&#xD;
             oral contraceptives, implantable contraceptives, intrauterine devices) during the&#xD;
             dosing period and for at least 4 months after the dosing period.&#xD;
&#xD;
         12. Ability to provide signed informed consent and willing and able to comply with all&#xD;
             study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Stage IIIB or IV NSCLC.&#xD;
&#xD;
          2. History or the presence of pulmonary interstitial disease, or drug-related&#xD;
             pneumonitis.&#xD;
&#xD;
          3. Malabsorption syndrome or other GI illness that could affect oral absorption of the&#xD;
             study drug&#xD;
&#xD;
          4. Inability to swallow oral medications&#xD;
&#xD;
          5. Have significant, uncontrolled or active cardiovascular disease, specifically&#xD;
             including but restricted to:&#xD;
&#xD;
               -  Myocardial infarction (MI) within 6 months of trial enrollment&#xD;
&#xD;
               -  Unstable angina within 6 months of trial enrollment&#xD;
&#xD;
               -  Congestive heart failure (CHF) with 6 months prior to trial enrollment&#xD;
&#xD;
               -  Any history of ventricular arrhythmia&#xD;
&#xD;
               -  Cerebrovascular accident or transient ischemic attack within 6 months of D1 of&#xD;
                  treatment&#xD;
&#xD;
               -  Clinically significant atrial arrhythmia or severe baseline bradycardia defined&#xD;
                  as resting heart rate &lt; 50 beat per minute&#xD;
&#xD;
               -  Uncontrolled hypertension defined as baseline SBP&gt; 160 and DBP &gt; 100 on 3&#xD;
                  separate clinic visits or past history of hypertensive urgency, emergency or&#xD;
                  encephalopathy&#xD;
&#xD;
          6. Have active infection requiring antibiotics&#xD;
&#xD;
          7. Pregnant or lactating female.&#xD;
&#xD;
          8. Prior treatment with an ALK, ROS1 or MET inhibitor&#xD;
&#xD;
          9. Any prior anticancer therapy for this diagnosis&#xD;
&#xD;
         10. Any active cancer diagnosis (basal or squamous cell cancers allowed) within the last 5&#xD;
             years for which the patient is receiving active therapy or which is untreated. Any&#xD;
             cancer diagnosis within the last 5 years that is considered &quot;treated&quot; and/ or on&#xD;
             surveillance may be included in the trial.&#xD;
&#xD;
         11. Have any condition or illness that, in the opinion of the investigator would&#xD;
             compromise patient safety or interfere with evaluation of the study drug (including&#xD;
             but not limited to HIV and HCV)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tejas Patil, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 17, 2017</study_first_submitted>
  <study_first_submitted_qc>March 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2017</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crizotinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 16, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT03088930/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

